Concept
Population selection to track outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
- 100 patients admitted to Spedali Civili of Brescia, a 1570-bed university hospital in Brescia, Italy in the hard-hit Lombardy region
- Requirements
- Hospitalized between March 9-20
- Diagnosis with COVID-19 pneumonia
- Disease assessed as "severe" according to BCRSS
- No contraindications for TCZ use
0
1
Updated 2020-06-15
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Brescia COVID-19 Respiratory Severity Scale (BCRSS)
Tocilizumab (TCZ) infusion dosage for study of outcomes among 100 severe COVID-19 patients in Brescia, Italy
Other concurrent therapies in evaluating outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
Population selection to track outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion